+44 208 677 4533 jarbuckle@blackswan-pharma.com

Black Swan Pharmaceuticals

homeimg

Black Swan PharmaceuticalsDeveloping the next generation of RNA-targeted therapeutics:

Formed in 2018, Black Swan Pharmaceuticals (BSP) is dedicated to discovering and progressing innovative gene targeting RNA based therapeutics called splice switching oligonucleotides (SSOs) for the treatment of amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Our SSOs have significant potential to help patients since they have been developed using techniques that precisely target key genes that are directly involved in causing both ALS and PD.